The all-in-one platform to find and track your stocks and investments
Discover the features
Statistics
Market Cap
255 billion
PE Ratio
25.08 x
Beta (volatility)
0.17
Earnings Per Share
1.58
About
ISIN : US7711951043
It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology,...
Price
Performance Comparison
| Roche Holding Ltd ADR | |
|---|---|
| 1 year return |
+14 %
|
| 5 years return |
+3 %
|
Valuation
| Price to Book | Payout ratio | PEG Ratio |
|---|---|---|
| 6.46 | 94 % | 0.72 |
| Price to Sales | Price / FCF | E.V.R. |
|---|---|---|
| 4.08 | 3.64 |
Price–Earnings Ratio History
The Price–Earnings Ratio history is not available for this stock.
Dividend History
Uninter. Dividend
21 years
Frequency
1x / year
Dividends in 2024
March
Dividends in 2023
March
March
Dividends in 2023
March
Forward Annual Amount
$1.39
Ex-dividend
3/28/2025
Sales segmentation
Financials
Year-over-Year growth
Profitability
Health
News
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
6/20/2025
Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
6/20/2025
Lower interest rates, drug pricing reform clarity are catalysts for biotech M&A market
6/19/2025
FDA's Prasad becoming agency's chief medical and scientific officer
6/19/2025
MAIA Biotechnology, Roche sign supply agreement for cancer therapies
6/19/2025
FDA's Makary talks up modernizing agency to get drugs to market faster
6/17/2025
Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)
6/17/2025
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
6/17/2025
Genentech And AbbVie: Venclexta Combo Fails To Extend Survival In Phase III Trial For High-Risk MDS
6/17/2025
Genentech Provides Update on Phase III Verona Study
6/16/2025
AbbVie fails in late-stage trial for Roche-partnered blood cancer therapy venetoclax
6/16/2025
RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
6/16/2025
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy • Terms and Conditions
© Copyright 2020-2025 Epsylia OÜ - All rights reserved
Moning is a platform that does not manage any funds and is purely educational. We do not provide any investment advice.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.